Odyssey
  • Homepage
  • Objectives
  • News
  • Publications
  • Privacy
    • Privacy Policy
    • Cookie Policy
  • Contact
  • Restricted
Select Page
Data from ODYSSEY are used by ViiV Healthcare to file FDA and EMA submissions for the first-ever dispersible formulation of dolutegravir for children living with HIV

Data from ODYSSEY are used by ViiV Healthcare to file FDA and EMA submissions for the first-ever dispersible formulation of dolutegravir for children living with HIV

by Communication Team | Dec 20, 2019 | ODYSSEY

Using data from the ongoing P1093 and the ODYSSEY (PENTA20) study, ViiV Healthcare has filed submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV. If approved, this new formulation of dolutegravir...

Recent Posts

  • Cheaper HIV treatment for children: a report in the Lancet
  • European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV
  • ODYSSEY trial data published in Lancet – shows increase in treatment options for older children living with HIV
  • Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
  • Dolutegravir for Children living with HIV

Recent Comments

    Archives

    • December 2020
    • November 2020
    • August 2020
    • June 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • March 2019
    • July 2018
    • June 2018
    • April 2018
    • August 2017
    • September 2016

    Categories

    • ODYSSEY
    • Publication

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    This study is funded by ViiV Healthcare and the sponsor is PENTA Foundation